Capital expenditures incurred but not yet paid
West Pharmaceutical Services Capital expenditures incurred but not yet paid increased by 866.7% to $26.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 30.4%, from $37.50M to $26.10M. Over 3 years (FY 2021 to FY 2024), Capital expenditures incurred but not yet paid shows an upward trend with a 11.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase indicates a growing pipeline of capital projects or equipment acquisitions that will require future cash settlement.
Detailed definition
This metric captures capital expenditures that have been committed to or incurred but for which cash payment has not yet...
Peer comparison
Commonly found in the supplemental cash flow disclosures of capital-intensive manufacturing firms.
amd_capex_unpaidHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.28M | $10.28M | $10.28M | $8.30M | $8.30M | $8.30M | $8.30M | $13.33M | $13.33M | $13.33M | $13.33M | $45.70M | $0.00 | $8.70M | $2.70M | $37.50M | $2.70M | $26.10M |
| QoQ Change | — | +0.0% | +0.0% | -19.2% | +0.0% | +0.0% | +0.0% | +60.5% | +0.0% | +0.0% | +0.0% | +243.0% | -100.0% | — | -69.0% | >999% | -92.8% | +866.7% |
| YoY Change | — | — | — | — | -19.2% | -19.2% | -19.2% | +60.5% | +60.5% | +60.5% | +60.5% | +243.0% | -100.0% | -34.7% | -79.7% | -17.9% | -69.0% | -30.4% |
Capital expenditures incurred but not yet paid at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's capital expenditures incurred but not yet paid?
- West Pharmaceutical Services (WST) reported capital expenditures incurred but not yet paid of $26.10M in Q1 2026.
- How has West Pharmaceutical Services's capital expenditures incurred but not yet paid changed year-over-year?
- West Pharmaceutical Services's capital expenditures incurred but not yet paid decreased by 30.4% year-over-year, from $37.50M to $26.10M.
- What is the long-term trend for West Pharmaceutical Services's capital expenditures incurred but not yet paid?
- Over 3 years (2021 to 2024), West Pharmaceutical Services's capital expenditures incurred but not yet paid has grown at a 11.6% compound annual growth rate (CAGR), from $41.10M to $57.10M.
- What does capital expenditures incurred but not yet paid mean?
- Capital investments made during the period that have not yet been paid for in cash.